Oncolytic virotherapy needs trials, not access programs
- PMID: 23549877
- DOI: 10.1158/1078-0432.CCR-13-0571
Oncolytic virotherapy needs trials, not access programs
Abstract
Oncolytic virotherapy is a novel treatment for cancer that exerts direct lytic and indirect immune-mediated antitumor effects. A Finnish research team has reported on an advanced therapy access program for oncolytic adenovirus. The strengths and weaknesses of this approach are highlighted with a view to informing future study conduct.
©2013 AACR
Comment in
-
Oncolytic virotherapy trials--letter.Clin Cancer Res. 2013 Aug 15;19(16):4541-2. doi: 10.1158/1078-0432.CCR-13-1471. Clin Cancer Res. 2013. PMID: 23946419 No abstract available.
Comment on
-
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.Clin Cancer Res. 2013 May 15;19(10):2734-44. doi: 10.1158/1078-0432.CCR-12-2546. Epub 2013 Mar 14. Clin Cancer Res. 2013. PMID: 23493351 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources